Live
FierceBiotechHow Unlearn is building a scientific intelligence layer for clinical developmentFierceBiotechHow AI is reshaping biopharma decision-makingFierceBiotechBiopharma IPOs: Timing, capital and staying flexibleRoche MediaRoche signs $2.3bn blood cancer drug agreement with Nurix Therapeutics - Pharmaceutical TechnologyEndpoints NewsIncyte to buy bleeding disorder biotech Vega Therapeutics in $1.25B upfront dealEndpoints NewsTakeda says it expects to take $2.5B hit after Amitiza antitrust verdict, with plans to appealEndpoints NewsNurix to work with Roche on BTK degrader in deal worth up to $2.3BFierceBiotechADA: Boehringer execs claim survodutide tolerability 'consistent' with class despite phase 3 updateFierceBiotechRoche bets $700M upfront on Nurix’s late-phase BTK degrader to tee up Lilly showdownBioPharma DiveInnovation alone is no longer enough in biopharmaBioPharma DivePrecision under pressure: Logistic solutions for nuclear medicine scalabilityLonza NewsLonza and Stipple Bio strike licensing deal for precision oncology ADCs - BioXconomy
Endpoints News Dec 30, 2025

Biotech’s groove is back for 2026 as XBI surges on M&A and lower rates

Biotech’s groove is back for 2026 as XBI surges on M&A and lower rates

Original
Body unavailable. Use the original source.